Biomarker Guided Therapies in Stage A/B Heart Failure
Status:
Completed
Trial end date:
2020-12-15
Target enrollment:
Participant gender:
Summary
Despite advances in cardiovascular care, the occurrence of heart failure (HF) is steadily
increasing. The increase in HF rates poses enormous challenges, as once an individual becomes
symptomatic or requires hospitalization with HF, the prognosis remains poor. Therefore,
prevention of HF is essential. HF prevention is a critical issue as HF risk factors that
include common medical conditions such as hypertension and diabetes are also increasing.
However, not everyone with these risk factors develops HF. Using novel blood tests, the
investigators propose to identify and treat subjects at higher HF risk to see if the
investigators can stabilize or improve ultrasound measures known to be associated with HF
risk. This study will enroll only Veterans.